+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effects of Rezpegaldesleukin in people aged 12 years and older who have moderate to severe atopic dermatitis. This Phase 3, randomized, double-blind study compares Rezpegaldesleukin to a placebo to assess its impact on skin symptoms and severity over approximately 15 months. The goal is to better understand how this treatment influences the condition in participants who have not responded well to topical therapies. Participants will receive Rezpegaldesleukin or a placebo by subcutaneous injection during an induction period every 2 weeks. This is followed by a maintenance period with Rezpegaldesleukin given either every 4 or 12 weeks or placebo every 4 weeks. There is also an open-label escape phase where dosing frequency of Rezpegaldesleukin is adjusted by the investigator. Treatments are administered under blinded conditions during the induction and maintenance phases. During the study, participants will have their skin condition evaluated through assessments like the Investigators Global Assessment IGA and Eczema Area and Severity Index EASI. Other measurements include itch and skin pain scales, sleep quality, and questionnaires related to asthma and sinus symptoms. Safety is monitored by tracking adverse events through about week 56 of participation. The overall study duration for each participant is about 15 months.

Age: 12Years +All GendersPhase 3
13 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety of two drugs, Deucravacitinib and Ustekinumab, in adults with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic treatments. This study is designed to compare these treatments over an extended period, focusing on cardiovascular health and other safety outcomes. The study is sponsored by Bristol-Myers Squibb and is a Phase 3b4 randomized, open-label trial. Participants are randomly assigned to receive either Deucravacitinib or Ustekinumab at specified doses on scheduled days. The study spans up to 5 years, during which participants will be monitored closely for cardiovascular events and other safety outcomes. Treatment adherence and effects will be regularly assessed throughout this long-term safety study. During the study, participants will undergo various evaluations including monitoring for major cardiovascular events such as heart attacks and strokes, other cardiovascular complications, and laboratory assessments including liver function and lipid panels. Researchers will also track serious adverse events and overall mortality up to 60 days after the last dose. This comprehensive monitoring ensures participant safety and gathers essential data on the long-term effects of the treatments over the studys duration, which lasts until January 2031.

Age: 40Years +All GendersPhase 3
411 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
E

Actively Recruiting

Researchers are evaluating the investigational drug RAP-219 in adults with focal seizures to determine its safety and effectiveness in reducing the frequency of these seizures. This Phase 3 study involves participants diagnosed with focal epilepsy, aiming to compare different doses of RAP-219 against a placebo. The study is designed as a randomized, double-blind, placebo-controlled trial to rigorously assess treatment outcomes. Participants will be randomly assigned to one of three groups high dose RAP-219, medium dose RAP-219, or placebo, all given as daily oral tablets. After completing the 14-week double-blind treatment period, participants may join an open-label extension study for long-term safety monitoring or enter an 8-week post-treatment follow-up period. This structure helps assess both immediate and ongoing effects of the drug. During the trial, participants will keep daily seizure records using an electronic diary to track focal seizure activity. Researchers will monitor seizure frequency changes from baseline to the end of treatment, focusing on median percent change and responder rates with at least 50% reduction. Additional assessments include seizure-free intervals and safety evaluations throughout the study and follow-up periods, lasting until study completion in 2029.

Age: 18Years - 75YearsAll GendersPhase 3
18 locations
E

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and immune response of an Acne mRNA vaccine in adults aged 18 to 45 years with moderate to severe acne. This Phase III study is the first to test this vaccine in humans and aims to find the best dose to use in future larger trials. Acne is a common inflammatory skin condition that affects millions worldwide, and current treatments have not changed much over the past 30 years. This study is sponsored by Sanofi Pasteur, a Sanofi Company. The trial includes up to three intramuscular injections of the Acne mRNA vaccine at different dose levels. Participants are divided into four groups two groups receive two injections and two groups receive three injections. Each vaccination group has a matching placebo group for comparison. The Core Study includes Sentinel and Main cohorts for both the two- and three-dose regimens. After completing the Core Study, some participants will enter a long-term follow-up period lasting up to 30 months to assess lasting effects of the vaccine. One group will be invited to join a separate long-term extension study. During the study, participants will be closely monitored for side effects shortly after each injection and for several months thereafter. Researchers will measure changes in the number of acne lesions and immune responses through blood tests. Safety assessments include tracking any adverse events and laboratory test results. Visits will include medical evaluations and questionnaires. The total participation time may extend beyond the Core Study to include long-term follow-up for some participants, lasting up to 38 to 40 months after the first injection.

Age: 18Years - 45YearsAll GendersPhase 1Phase 2
94 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the impact of telehealth self-management coaching sessions on the quality of life of pancreatic cancer survivors and their family caregivers. Pancreatic cancer patients often face numerous symptoms from the disease and its treatment, which can negatively affect their quality of life. This study aims to address unmet needs by providing support in managing physical symptoms, emotional, social, and spiritual well-being through remote coaching. Participants will be divided into two groups one group will attend telehealth self-management coaching sessions lasting 40 to 60 minutes every other week for a total of six sessions over three months. The other group will receive standard care. Both patients and their family caregivers are included in the coaching sessions, which are designed to help with symptom management and caregiver support. During the study, participants will complete questionnaires to report on quality of life, symptom severity, psychological distress, caregiving burden, and overall survival. These assessments occur at the start of the study and at 3 and 6 months after randomization. The study monitors enrollment, session completion, participant experiences, and follow-up rates over up to six months, with the total study duration lasting three months for the coaching sessions and follow-up assessments continuing thereafter.

Age: 18Years +All GendersPhase Not Applicable
22 locations